Biotest is a company specialising in innovative haematology and immunology products with the holistic approach of a global pharmaceutical and biotherapeutics group. Its approximately 1,700 employees develop, manufacture and sell medicinal products for the treatment of blood and immune diseases.

The most important starting material for our pharmaceutical products is human blood plasma which we process into effective and highly pure medicinal products in one of the world’s most modern production facilities in Europe. Our products are used in the treatment of life-threatening diseases such as coagulation disorders (haemophilia), severe infections or disorders of the immune system. One of our highest priority research projects is the development of monoclonal antibodies, active substances produced by biotechnological techniques, which will open up new prospects in the treatment of rheumatism, leukaemia and other autoimmune diseases.

Biotest products meet the highest standards and are sold in markets which have to satisfy the most stringent registration requirements in the world. Patients, hospitals, medical practices in 159 countries around the globe put their trust in Biotest’s quality and safety.